Molecular and Cellular Mechanisms of Antidepressant Action
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
A long-standing theory is that brain monoamine signalling is critically involved in the mechanisms of antidepressant drug treatment. Theories on the nature of these mechanisms commenced with ideas developed in the 1960s that the drugs act simply by increasing monoamine availability in the synapse. However, this thinking has advanced remarkably in the last decade to concepts which position that antidepressant drug action on monoamine signalling is just the starting point for a complex sequence of neuroadaptive molecular and cellular changes that bring about the therapeutic effect. These changes include activation of one or more programmes of gene expression that leads to the strengthening of synaptic efficacy and connectivity, and even switching neural networks into a more immature developmental state. It is thought that through this increase in plasticity, key neural circuits within the limbic system are more easily remodelled by incoming emotionally relevant stimuli. This article attempts to bring together previous and current knowledge of antidepressant drug action on monoamine signalling at molecular and cellular levels, and introduces current thinking that these changes interact with neuropsychological processes ultimately to elevate mood.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“It is also proposed that increased production of newly formed neurones is one of the endpoints of the gene expression changes that are critical to the therapeutic effect of antidepressant treatment (Santarelli et al. 2003).”
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“Initial studies demonstrated that repeated antidepressant treatment to rodents increased expression of brain-derived neurotrophic factor (BDNF) (Lindefors et al. 1995; Nibuya et al. 1995).”
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Delgado, P. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810170011002 · Cited by 924
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Trambaiolli, L. R., Kohl, S. H., Linden, D. E. J., & Mehler, D. M. A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.015 · Cited by 87
Mexican medicinal plants with anxiolytic or antidepressant activity: Focus on preclinical research
López‐Rubalcava, C., & Estrada-Camarena, E. M. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.03.053 · Cited by 71
Mechanisms of SSRI Therapy and Discontinuation
Sharp, T., & Collins, H. (2023) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2023_452 · Cited by 55
Self-citationIntermediate phenotypes and biomarkers of treatment outcome in major depressive disorder
Leuchter, A. F., Hunter, A. M., Krantz, D. E., & Cook, I. A. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/aleuchter · Cited by 41
Zhou, Q., Li, X., Yang, D., Xiong, C., & Xiong, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114431 · Cited by 43
Resende, R., Fernandes, T., Pereira, A. C., Pascale, J. D., Marques, A. P., Oliveira, P., Morais, S., Santos, V. L. C. D. G., Madeira, N. G. G. F., Pereira, C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165752 · Cited by 42
Micale, V., Bartolomeo, M. D., Martino, S. D., Štark, T., Dell’Osso, B. M., Drago, F., & D’Addario, C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108279 · Cited by 41
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Guillén-Ruiz, G., Cueto‐Escobedo, J., Limón-Vázquez, A. K., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2024) · Biomedicines · doi:10.3390/biomedicines12122744 · Cited by 42
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Manosso, L. M., Duarte, L. A., Martinello, N. S., de Mathia, G. B., & Réus, G. Z. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273254093231020052002 · Cited by 29
Rebound activation of 5-HT neurons following SSRI discontinuation
Collins, H., Gullino, L. S., Ozdemir, D., Lazarenco, C., Sudarikova, Y., Daly, E., Pilar-Cuéllar, F., Pinacho, R., Bannerman, D. M., & Sharp, T. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01857-8 · Cited by 26
Self-citationKato, M., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., Nishida, K., Nonen, S., Higasa, K., & Kinoshita, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073873 · Cited by 23
Zeng, J., Wang, Z., Zhang, X., Zhao, A., Qi, H., Jiang, Y., Cai, D., & Zeng, N. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156927 · Cited by 22
Dicarlo, M., Pignataro, P., Zerlotin, R., Suriano, C., Zecca, C., Dell’Abate, M. T., Storlino, G., Oranger, A., Sanesi, L., Mori, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119111 · Cited by 22
Guirado, R., LaTerra, D., Bourguignon, M., Carceller, H., Umemori, J., Sipilä, P., Nácher, J., & Ċastrén, E. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00022 · Cited by 19
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice
Collins, H. M., Pinacho, R., Ozdemir, D., Bannerman, D. M., & Sharp, T. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093032 · Cited by 15
Self-citationThe Association of Salivary Serotonin With Mood and Cardio-Autonomic Function: A Preliminary Report
Karbownik, M. S., & Hicks, S. D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.788153 · Cited by 13
Moustardas, P., Abbasi, M., Javidjam, D., Asamoah, C. S., Schweitzer-Chaput, A., Cisternino, S., Brémond‐Gignac, D., Aberdam, D., & Lagali, N. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.08.008 · Cited by 11
Arafat, M., Moon, N. J., Mohammad, M., Mamun, M. J. I., Meem, J. N., Rasel, M., Uddin, B., Momen, M. S. H., Ali, M. L., Hoque, N., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70185 · Cited by 11
Chen, C., Ding, H., Mabry, K. M., & Ko, M. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173341 · Cited by 10
Cook, I. A., Congdon, E. L., Krantz, D. E., Hunter, A. M., Coppola, G., Hamilton, S. P., & Leuchter, A. F. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00870 · Cited by 10
Zhu, Z., Cheng, Y., Han, X., Wang, T., Zhang, H., Yao, Q. Z., Chen, F., Gu, L., Yang, D., Chen, L., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c00415 · Cited by 10
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Liu, R., Liu, N., Ma, L., Liu, Y., Huang, Z., Peng, X., Zhuang, C., Niu, J., Yu, J., & Du, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01123-x · Cited by 8
Fang, Y., & Mao, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_1 · Cited by 6
Islam, M. M., Hossain, M. J., Zahan, M. S., Nur, F., Al-Mansur, M. A., & Rashid, M. A. (2023) · Bangladesh Pharmaceutical Journal · doi:10.3329/bpj.v26i1.64215 · Cited by 3
Noda, S., Nakagawa, A., Umeda, S., Amano, M., Nogami, W., Ihara, S., Kobayashi, Y., Ozawa, M., Takemura, R., Uchida, H., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1671393 · Cited by 1
Brain Proteomic Analysis on the Effects of the Antidepressant Fluoxetine
Guest, P. C. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0471-7_31 · Cited by 1
Impaired mitochondrial bioenergetics in psychiatric disorders
Petschner, P., Gál, Z., & Gonda, X. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00008-5 · Cited by 1
Depression management and pharmacoepigenetics
Walker, S. A., Su, A., & Kamath, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823039-8.00002-2 · Cited by 1
Valdameri, B. (2023) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 2
Clinical research Intermediate phenotypes and biomarkers of treatment outcome in major depressive
Hunter, A. M., Krantz, D. E., & Cook, I. A. (2014)
Neurotransmitters and signalling
Sharp, T. (2020) · doi:10.1093/med/9780198713005.003.0014
Self-citationAttia, H., Aati, H. Y., Babtin, R. M., Al-Qahtani, N. M., Alomar, H. A., Arafah, M., Ali, R., & Wanner, J. (2025) · Arabian Journal of Chemistry · doi:10.25259/ajc_133_2024
Neurotechnologies in Anxiety and Depression: Advances in Treatment and Personalized Care
Chaudhary, U. (2025) · Springer eBooks · doi:10.1007/978-3-031-78991-5_7
Investigação da toxicidade e atividade antidepressiva-símile do o-Eugenol em camundongos fêmeas
de Abrantes, A. F. F. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Sharp, T.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Sharp, Trevor
- ORCID
- Sharp, Trevor
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012
- Volume
- 14
- Pages
- 309-325
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W1490282579
- Semantic Scholar
- 0e603e834835e77a93a98b41744375d1dd843771
- Cited by
- 36
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 1 · 2016: 3 · 2015: 1 · 2014: 2
- FWCI
- 2.93
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antidepressant mechanism, synaptic plasticity, neural adaptation, gene expression, synaptic efficacy, neural network development, limbic system, mood regulation, emotional stimuli, neuropsychology
- MeSH terms
- Animals, Antidepressive Agents, Brain, Humans, Neuronal Plasticity, Neurons, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.